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Abstract: The treatment of patients with drug-eluting stents (DES) continues to evolve with 
the current emergence of DES technology that offers a combination of pharmacological and 
mechanical approaches to prevent arterial restenosis. However, despite the promising short-
term and mid-term outcomes of DES, there are valid concerns about adverse clinical effects 
of late stent thrombosis. In this study, we present an example of how nanomedicine can offer 
solutions for improving stent coating manufacturing, by producing nanomaterials with tailored 
and controllable properties. The study is based on the exploitation of human platelets response 
towards carbon-based nanocoatings via atomic force microscope (AFM). AFM can facilitate the 
comprehensive analysis of platelets behavior onto stent nanocoatings and enable the study of 
thrombogenicity. Platelet-rich plasma from healthy donors was used for the real-time study of 
biointerfacial interactions. The carbon nanomaterials were developed by rf magnetron sputtering 
technique under controllable deposition conditions to provide favorable surface nanotopography. 
It was shown that by altering the surface topography of nanocoatings, the activation of platelets 
can be affected, while the carbon nanocoatings having higher surface roughness were found to 
be less thrombogenic in terms of platelets adhesion. This is an actual solution for improving 
the stent coating fabrication.
Keywords: stents nanomedicine, carbon coating, atomic force microscopy platelets 
nanotechnology
Introduction
Coronary drug-eluting stents (DES), being the new gold standard for percutaneous 
coronary revascularization, offer a benefit in reducing the acute vessel closure, reste-
nosis and the need for repeat hospitalization, heart catheterizations and bypass surgery. 
A critical reassessment of the published evidence, however, suggests that the putative 
superiority of intravascular DES is founded on a questionable premise.1 Specifically, 
late stent thrombosis (30 days post procedure) in patients who receive DES is a 
primary area of interest because of the potential for serious adverse outcomes such 
as myocardial infarction and sudden death in an estimated 45% of these cases.2 This 
effect has been reported to occur at a rate of 0.2%/year in clinical trials3 and 0.6%/year 
with off-label use of DES in clinical practice.4
A possible higher rate of late thrombosis of the DES in comparison with bare 
metal stents has been shown recently. Indeed, nonclinical trial data show higher DES 
late thrombosis rates than those observed with bare metal stents.5 One of the pos-
sible mechanisms of DES late thrombosis is suggested to be the platelets activation 
and inflammatory reaction of the vessel wall associated with DES, either due to the International Journal of Nanomedicine 2010:5 240
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polymers, the drug coatings themselves, or perhaps both. 
From a histological perspective, although DES can halt 
smooth muscle cells migration and proliferation owing to 
their antiproliferative drug elusion, in some cases they impair 
the re-endothelalization process with localized thrombus for-
mation as observed with angiography or on histopathologic 
specimen.6 Rare occurrence of an eosinophilic reaction was 
described that might have led to late stent thrombosis and 
caused negative clinical outcomes.7
Besides the more widespread “off-label” use of DES 
and of the early discontinuation of antiplatelet therapy, 
different stent properties can subtly affect stent function, 
including modular design, metal coverage, strut thickness, 
strut shape, surface smoothness, coating materials, and drug 
properties.8 In addition to microscale stent surface features, 
the nanoscale surface texture, tailored through the deposition 
conditions of the nanocoatings, may be useful for improving 
stent function, given that the surface topography can promote 
vascular smooth muscle cell and endothelial cell adherence 
and proliferation.9,10 Several such coatings have been gener-
ated using a sol-gel process, in which a colloidal suspension 
(sol) of metal or ceramic is applied to a surface by dipping or 
spraying and subsequently bonded to form a porous, highly 
textured coating, such as titanium dioxide. Nanotextured coat-
ings fit into a category of design concept that enhance endo-
thelialization of stent struts and may reduce late thrombosis.11 
Thus nanotechnology, an emerging multidisciplinary field of 
science that manufactures, studies and manipulates matter 
on a nanoscale, deals with the surface optimization of stents, 
by designing and developing biocompatible nanocoatings, 
as the first-layer cell formation on the surface is essential to 
minimize blood clotting. Nano approaches will allow the syn-
thesis and control of materials in nanometer dimensions, and 
the in-depth analysis of bio/non-bio interactions via imaging 
nanotools providing access to new materials properties and 
stent characteristics in unprecedented ways.12 Polymeric drug 
barriers for stents are considered to have drawbacks due to 
the delay in endotheliazation of stent surface, which causes 
inflammatory reaction of the arterial wall. Therefore much 
research is being done on organic and inorganic thin films 
such as carbon-based coatings for artificial heart valves, 
blood pumps and stents.13,14
Here we describe the manufacture of two types of car-
bon nanocoatings using rf magnetron sputtering deposition 
technique with variation in surface roughness as the main 
variable for the control of platelets response. An atomic 
force microscope (AFM) was used in order to investigate 
the thrombogenicity of the amorphous hydrogenated carbon 
(a-C:H) thin films and the role of tuning the deposition 
conditions for favorable surface nanostructure to inhibit 
thrombosis.
Methods
To manufacture the biomaterials, amorphous hydrogenated 
carbon nanocoatings, 80 nm thick, were deposited on sili-
con and stainless steel wafers by radio frequency reactive 
magnetron sputtering in a high vacuum chamber, in Ar/H2 
atmosphere by varying the hydrogen content (from 5% to 
20% H2). Two types of carbon thin films were developed 
under different deposition conditions: type A carbon nano-
coatings with the application of ion bombardment on the 
substrate during deposition and type B carbon nanocoatings, 
without applying ion bombardment.
For the cell adhesion study, human platelet rich plasma 
(PRP) was prepared after the centrifugation of whole blood at 
800 rpm for 7 to 10 minutes at room temperature (RT). The 
blood was drawn by venopuncture from healthy donors who 
did not take aspirin or clopidogrel or other drugs that affect 
platelets function. Then, the PRP was diluted with homolo-
gous plasma at a ratio of 1:1000. The a-C:H nanocoatings 
were cleaned by N2 flow to remove any contaminants and 
incubated in PRP at RT. Then they were examined by AFM, 
after fixation of platelets with 5 µL glutaraldehyde 1% at 
1- and 2-hour intervals in order to acquire an AFM image 
of their morphology at a specific time. The SOLVER P47H 
scanning probe microscope (NT-MDT) was implemented in 
ambient environment, and to avoid platelets destruction by 
the sharp conical tip of AFM, the semi contact/tapping scan-
ning mode of AFM was employed. AFM is a high-resolution 
microscopy, with demonstrated resolution of fractions of a 
nanometer, more than 1000 times better than that of optical 
microscopy, which is restricted by the optical diffraction limit. 
Unlike other imaging techniques such as scanning electron 
microscopy (SEM), this nanotool enables the biological enti-
ties–materials interactions to be investigated with nanoscale 
precision.15 While an electron microscope needs an expensive 
vacuum environment for proper operation, AFM can work 
perfectly well in ambient air or even a liquid environment, 
enabling cells to be studied in their near native environment 
without the need for special preparation, and guarantees cell 
viability.16 It can also provide size characterization in all three 
spatial dimensions, because it provides direct information 
about the height as well as lateral dimensions of the examined 
biological samples.
The AFM probe is a microscale cantilever with a sharp 
tip at its end (nominal tip radius ∼ 10 nm) which is used to International Journal of Nanomedicine 2010:5 241
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scan the specimen surface. An ionic repulsive force from the 
surface applied to the tip bends the cantilever upwards, and 
the amount of bending, measured by a laser spot reflected on 
to a split photo detector, can be used to calculate the force. 
By keeping the force constant while scanning the tip across 
the surface, the vertical movement of the tip follows the 
surface profile and the surface topography is acquired. In 
semi-contact scanning mode used in this study, the cantilever 
vibrates and thus taps the sample surface point after point 
without causing any destruction.17
The morphology of the adherent platelets, as an index of 
their activation, was investigated at 1- and 2-hour intervals 
and 10 fields were chosen at random to obtain statistical 
averages of the adherent platelets (by Student’s t-test). The 
quantities used for the evaluation of surface roughness of the 
bare films and during platelets adhesion were peak to peak 
distance (peak-to-peak), and root-mean-square roughness 
(Rrms). Quantitative and qualitative data provided from AFM 
imaging are highly informative for evaluating thrombogenic-
ity of the case-study materials, whose selection was based 
on the fact that the carbon-based materials with an increased 
fraction of sp3 bonds are known to possess high mechanical 
hardness, chemical inertness and low friction coefficient, and 
have also shown good blood compatibility.18 In our previ-
ous work, we deduced that a-C:H thin films with 42% sp3 
hybridized carbon bonds content and a small amount of H2 
in plasma during deposition exhibit good hemocompatibility 
on the scope of protein adsorption.19,20 In order to validate 
the AFM results, complementary SEM measurements with 
a 20 kV JEOL 840A SEM were made to visualize platelets 
on type A and type B carbon nanocoatings with 5% H2 in 
plasma during deposition after 1 hour of incubation.
As proteins and cells determine biomaterials thrombo-
genicity, these results create a basis for investigating further 
the interfacial phenomena of platelets interactions with the 
selected carbon nanocoatings.
Results
The implantation of biomaterials into the human body is 
followed by a surge of proteins and cells to cover their 
surface, and bioreactions with the surrounding biological 
tissue, which are governed by the implant surface. The first 
major event after a medical device comes in contact with 
blood is the adsorption of plasma proteins that tune the 
cell adhesion and behavior.21 Platelets adhesion followed 
by aggregation and spreading is the prerequisite event for 
thrombus formation, which impairs the implant’s length of 
life. For vascular stents, heart valves and pumps that come 
in direct contact with blood, platelets behavior is a key issue 
for the evaluation of hemocompatibility of biomaterials. This 
study focuses on the morphological changes and interactions 
of human platelets with nanomaterials (a-C:H nanocoatings) 
probed by AFM.
At first, for AFM characterization of platelets adhesion 
on to the selected carbon nanocoatings, it should be men-
tioned that the platelets are disc shaped, and 0.5 to 3 µm in 
size. After they come in contact with an artificial material 
and become activated, their shape becomes flatter, their 
granules are gathered into the center of the cell contribut-
ing to the composition of pseudo nucleus (‘egg-like’ type), 
and broad pseudopodia are extended. The elaboration of 
filopods made by the assembly of new cytoplasmic actin 
filaments is essential for their spread on to surfaces and 
their aggregation. After platelet adhesion, the platelet release 
reaction takes place in the adhering platelets, releasing 
serotonin, thromboglobulin, platelet factor IV, thromboxane 
A2, which leads to platelet aggregation on the surface.22,23 
The previously mentioned morphological alterations of 
platelets during activation were taken into consideration 
for the analysis of the AFM images. Figures 1 and 2 show 
the stages of platelets activation. More precisely, in Fig-
ure 1, the platelet was activated after 15 minutes adhesion 
on carbon-based thin film and it lost its discoid shape and 
became spherical. Figure 2 shows highly activated platelets 
with filopods connected with each other forming a network, 
compromising a pre-stage of a thrombus. Figure 3a shows 
an AFM image of activated platelets with pseudopodia on 
carbon nanocoatings after 1 hour of incubation. For cell 
adhesion studies, AFM, being superior to other imaging 
methods, can provide information with nanoscale precision, 
as indicated, for instance, by performing an arbitrary sec-
tion of one activated platelet and measuring the height of its 
periphery with no filopods (170 nm), of its centre (220 nm) 
and its pseudopodia (100 nm) (Figure 3b).
By observing the AFM images of platelets adhering on 
to the selected carbon nanocoatings, it can be deduced that 
on the type B carbon thin films with 5% H2 in plasma dur-
ing deposition, after 1 and 2 hours incubation, the platelets 
undergo the following alterations in morphology during acti-
vation: i) loss of discoid shape, ii) extension of pseudopodia, 
iii) egg-like type formation, but without any development of 
aggregation (Figures 4a–b). In contrast, on type A carbon 
nanocoatings, it can be easily noticed in Figure 5a., that 
after 1 hour of incubation, platelets appear with a ‘pseudo 
nucleus’ in their center, being a index of activation, and 
after 2 hours they aggregate, forming a cluster look like an International Journal of Nanomedicine 2010:5 242
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Figure 1 Three-dimensional AFM topography image of platelets (in circles) on a-c:h nanocoating after 15 minutes of incubation, at an early stage of activation.
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Figure 2 Three-dimensional AFM topography image of activated platelets on a-c:h nanocoating after 2 hours of incubation, interconnected with pseudopodia.International Journal of Nanomedicine 2010:5 243
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‘island’ (Figure 5b). It can be easily seen that platelets have 
a higher tendency to aggregate on the type A than on type B 
carbon nanocoatings. If the content of H2 in plasma during 
deposition of type A nanocoatings is increased up to 20%, the 
observations of platelet AFM studies reveal that after 1 and 
2 hours of incubation, the platelets undergo morphological 
changes during activation and they form clusters as well 
with a greater height of more than 1000 nm (Figures 6a–b). 
The higher content of hydrogen in the plasma is associated 
with the AFM observations that the platelets tend to make 
higher clusters on their surfaces. These data derived from 
AFM observations were confirmed by the measurements of 
surface roughness of the biofilms. The comparative diagram 
of a time-dependent increase of peak-to-peak and root mean 
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Figure 3 A) Two-dimensional AFM topography image of activated platelets with pseudopodia on a-c:h nanocoating after 1 hour of incubation; B) Arbitary section (white line) 
in 3A, of one activated platelet (PLT) at three points (white circles) with measurements of its components.
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Figure 4 Three-dimensional AFM topography image of: A) Platelets on type B carbon nanocoating (after 1 hour incubation (scan size 10 µm × 10 µm).   The circle indicates 
an activated platelet having the egg-like type structure; B) Platelets on type B carbon nanocoating after 2 hours incubation time (10 µm × 10 µm).  The circles denote the 
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square roughness parameters (Figure 7) and is indicative of 
platelets’ gradual aggregation during time.
As a combination of parameters influence the response of 
blood components towards biomaterials, the nanotopography 
and surface roughness of the examined films were assessed 
to correlate with their thrombogenicity. The peak-to-peak 
and Rrms values of the bare a-C:H nanocoatings (without 
the platelets) are shown in Table 1 (P  0.001) type A car-
bon nanocoatings exhibit lower surface roughness than the 
type B nanocoatings, which can be attributed to the Ar+ ion 
bombardment of the growing nanocoating during deposition. 
In order to validate our results, SEM measurements were 
made for the visualization of platelets conformation on type 
A and B carbon nanocoatings with 5% H2 in plasma during 
deposition after 1 hour of incubation (Figure 8).
An inactivated platelet with spherical shape is presented 
in Figure 8a. As can be seen in Figure 8b, the platelets on 
type B carbon nanocoatings (with 5%H2 in plasma during 
deposition) remain inactivated as they do not form pseudopo-
dia or clusters, whereas on the type A nanocoatings, the cells 
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Figure 5 Three-dimensional AFM topography image of: A) Platelets on type A carbon nanocoating with 5% h2 in plasma during deposition, after 1 hour of incubation (scan 
size 10 µm × 10 µm), B) Platelets on the same coatings as in Figure 5A, after 2 hours incubation time (scan size 21 µm × 21 µm).   The arrows indicate the platelets aggregation 
and the formation of a cluster-like island.
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Figure 6 Three-dimensional AFM topography image of: A) Platelets on type A carbon nanocoatings with 20% h2 in plasma during deposition after 1 hour incubation (scan 
size 21 µm × 21 µm). They form aggregations as presented with the arrows, with a mean maximum height of approximately 659 nm, B) Platelets on type A carbon nanocoat-
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are more activated as they lose their spherical shape and 
increase their size, but still without forming clusters. These 
results are in accordance with the AFM images of the same 
samples after 1 hour of incubation (Figures 4a and 5a).
Discussion
The state-of-the-art in DES technology is mainly the 
production of stents that elicit a cytotoxic or cytostatic 
drug that inhibits smooth muscle cells proliferation of the 
arterial wall and extra-cellular matrix targeting to these 
cells in order to halt the restenosis cascade. As a result, 
long-term artery restenosis rate after DES stent implan-
tation is reduced.24–26 However, there are still concerns 
about the very late stent thrombosis of DES observed 
after 12 months of implantation, compared with bare 
metal stents.27 Although the cumulative incidence of stent 
thrombosis with DES at 9 to 12 months has ranged from 
0.5% to 0.7% in clinical trials, roughly comparable to the 
incidence with bare metal stents, after 12 months, this pat-
tern of thrombotic events was frequently observed beyond 
12 months with DES but not with bare metal ones.28 This 
complication of DES was attributed mainly to inadequate 
endothelialization due to polymer coatings or elusion of 
the antiproliferative drug. Thus, the stent surface treatment 
by the design of biocompatible novel nanocoatings and the 
in-depth knowledge of the cells–biomaterials interaction 
with nanoscale precision are two of the challenges of 
nanotechnology. This is an interdisciplinary scientific field 
which is considered to be the key technology of the 21st 
century, focusing on novel methods and materials, and 
tools with nanometer precision.
A number of nanotechnology approaches have been 
developed in stent technology.29,30 Stents with surface 
nanopores or nanoparticles with high stability and carrier 
capacity, and capable of incorporating both hydrophilic and 
hydrophobic substances in order to be used as carriers for 
bioactive factors and drugs have been manufactured. Many 
attempts have already been made to develop biodegradable 
or tissue-engineered and bioactive stents, which promote 
healing reactions by triggering the body’s natural processes.31 
Tissue engineering will enable biofunctionalized stents to 
create a biomimicking environment that promotes the desired 
endothelial cell activities, by exchanging the appropriate 
stimuli, and so promote their binding to specific endothelial 
membrane receptors.
Until now there has been a clear lack of data on the 
thrombogenicity of stent materials dictated by nanoscale 
observations. As thrombogenicity is a multiparametric pro-
cess, the present work tested the hypothesis on the influence 
of surface nanotopography on platelets activation in order 
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to manufacture less thrombogenic stent nanocoatings by 
tailoring their surface properties. AFM, also called the ‘eye 
of nanotechnology’, was implemented to give evidence of 
a real time study of platelets response towards biomaterials 
for enhancing hemocompatibility.
Since proteins and cells range in size from nano- to 
micrometer scales, these length scales should be observed 
by an imaging tool able to observe and manipulate molecular 
and atomic level features and which can be used for high-
resolution and real-time studies of bio- and non-bio interac-
tions. Until now, platelets studies were based on conventional 
biological imaging methods, such as SEM, which requires 
special preparation of the cells with gold and does not guar-
antee their viability. Therefore, a nondestructive, nanoscale 
precision technique for platelets study is needed, which can 
observe platelets in a native, unlabeled state for several hours 
without damage. One method that satisfies these demands 
is the AFM.32
An early event in blood–material interaction is the rapid 
and selective protein adsorption by a three-step process: the 
transport to the interface, the reaction of adsorption, and 
the conformational rearrangement. In addition, the implant-
associated protein adsorption and conformational changes 
have been shown to promote immune reactions, and the 
engineering of surface properties (physical and chemical 
characteristics) has been rigorously researched in order to 
reduce protein adsorption and cell interactions and subse-
quently improve implant biocompatibility.33
Previous studies in our laboratory have focused on 
protein adsorption on carbon thin films measured by AFM 
and spectroscopic ellipsometry techniques.34–36 Cells adhe-
sion occurs at a later stage and is mediated by the proteins 
initially adsorbed on the surface. Platelets, of the other cells 
present in blood, have the most important role in blood–
material interactions. A knowledge of basic cell–material 
interaction and an understanding of processes at the cellular 
level can aid in the development of new biomaterials with 
properties that can be prescribed and regulated.37 Therefore, 
there is a need to accumulate data on the interrelationship 
of physicochemical phenomena at biomaterial interfaces 
and their hemocompatible properties. The likelihood of 
the emergence of thrombosis caused by a biomaterial and 
especially the way that platelets react during their adhesion 
on to biomaterials, whether or not they activate the degree 
of activation and aggregation, are important parameters 
for hemocompatibility assessment, as proposed by ISO 
guidelines.38 Nevertheless, device-stent failure and/or other 
tissue–biomaterials interactions frequently cause clinically 
observable complications such as acute coronary syndrome, 
and necessitate reoperations or may be fatal. These deleteri-
ous outcomes may follow many years of uneventful benefit 
to the patient. Thus, there is a need for nanotechnology to 
contribute to the enhancement of thrombo-protectivity of 
stent nanocoatings by tailoring their properties on the basis 
of  monitoring nanoscale platelet–surface interactions.
Platelet adhesion to a surface is governed by two inde-
pendent mechanisms: the transport of platelets to the surface, 
which depends on the flow conditions, and the reaction of 
platelets with the surface, which depends on the nature of the 
surface and the adsorbed proteins. Platelet response after the 
contact of blood with an artificial surface is also influenced 
by diffusion, and intermolecular and shear forces. Platelets 
aggregation as described in this work may be attributed at first 
to the previous protein adsorption of PRP and the interaction 
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Figure 8 seM images of: A) a human platelet onto carbon substrate, B) inactivated platelets on type B carbon nanocoating with 5% h2 in plasma during deposition, after one 
hour of incubation and C) activated platelets on to type A carbon nanocoating with 5% h2 in plasma during deposition, after 1 hour of incubation.International Journal of Nanomedicine 2010:5 247
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of platelets with the adsorbed fibrinogen or γ-globulin due to 
the formation of a complex between glycosyltransfereases 
located in the platelet membrane and incomplete heterosac-
charides in the protein layer. Secondly, platelets connect with 
each other via filopods, and fibrinogen linkage with platelets 
surface receptors IIβ-IIIa, mediated by ATP and calcium. 
The formation of platelet islands may also be an outcome of 
intermolecular interactions, van der Waals, chemical, electro-
static forces (cell surface charge due to the content of sialic 
acid into their glycocalyx), and thermodynamic conditions 
involving the minimization of enthalpy and entropy.
In this work, we verified that nanotopography and surface 
characteristics influence the thrombogenicity of different 
types of carbon nanocoatings developed with magnetron 
sputtering, and that by tuning deposition parameters, throm-
bogenic behavior of the nanocoatings can be changed. All the 
aforementioned quantitative and qualitative data (variations 
in time-dependent platelets’ surface roughness and AFM 
images, respectively) show that the rougher type B carbon 
nanocoatings activate the platelets less than the smoother 
type A carbon nanocoatings, whereas the content of H2 in 
plasma during deposition affects hydrogen configuration, 
surface properties, carbon bonding and subsequently their 
biological behavior. The above AFM results were compared, 
validated and verified by SEM results.
Also, these findings are in accordance with our hemo-
compatibility studies on the protein adsorption and platelets 
adhesion on biomaterials, which have shown that the nanotop-
ography and surface roughness of biomaterials influence their 
biological behavior. Specifically, the carbon thin films with 
higher surface roughness were found to be more hemocompat-
ible as they exhibit higher albumin fibrinogen adsorption ratio 
as measured by spectroscopic ellipsometry,39,40 and a lower 
degree of platelets activation.30,36 Recent studies on diamond 
like carbon (DLC) stent coatings suggest that the smooth 
surface of stent nanocoatings may promote thrombosis and 
may not encourage re-endothelialisation and that the surface 
roughness is correlated with the antithrombogenicity of DLC 
films.41,42 Another study suggests that surface roughness of 
biomaterials is a key factor in influencing thrombogenicity, 
and the evaluation of the fluorine doping in DLC films showed 
significant reductions in platelet adhesion and activation com-
pared with DLC films for every grade of roughness.43
The hemocompatibility of an artificial material is an 
extremely complex and multiparametric process that it deter-
mines the efficacy of implants. Besides nanotopography44 and 
stoichiometry, we have found that wettability, and chemistry 
and surface electrical properties can also influence the fate 
of implants in the human body.45,46
Conclusions
This study has shown that the surface nanotopography of the 
stent nanocoating influences platelets behavior, which is a key 
factor for biomaterial thrombogenicity. Among the studied 
carbon nanocoatings those with the higher surface roughness 
value were found to be less thrombogenic in terms of platelets 
adhesion. Thus, by controlling the deposition conditions of 
the stent nanocoatings, the desirable surface properties that 
enhance their biological performance can be achieved. This 
is an example of how nanomedicine can revolutionize stent 
technology to meet the future challenge of late stent throm-
bosis, which is Achilles’ heel of vascular stents.
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